These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 28138633)

  • 21. Targeting angiogenesis for liver cancer: Past, present, and future.
    Zhu XD; Tang ZY; Sun HC
    Genes Dis; 2020 Sep; 7(3):328-335. PubMed ID: 32884987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy.
    Qin S; Li A; Yi M; Yu S; Zhang M; Wu K
    J Hematol Oncol; 2019 Mar; 12(1):27. PubMed ID: 30866992
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends and Challenges in Tumor Anti-Angiogenic Therapies.
    Jászai J; Schmidt MHH
    Cells; 2019 Sep; 8(9):. PubMed ID: 31540455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting angiogenesis in head and neck cancer.
    Seiwert TY; Cohen EE
    Semin Oncol; 2008 Jun; 35(3):274-85. PubMed ID: 18544442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perspectives on Treatment of Metastatic Colorectal Cancer with Immune Checkpoint Inhibitor Therapy.
    Morse MA; Hochster H; Benson A
    Oncologist; 2020 Jan; 25(1):33-45. PubMed ID: 31383813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions.
    Khan K; Cunningham D; Chau I
    Curr Drug Targets; 2017; 18(1):56-71. PubMed ID: 25808652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-angiogenesis in cancer therapeutics: the magic bullet.
    Oguntade AS; Al-Amodi F; Alrumayh A; Alobaida M; Bwalya M
    J Egypt Natl Canc Inst; 2021 Jul; 33(1):15. PubMed ID: 34212275
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Current and emerging anti-angiogenic therapies in gastrointestinal and hepatobiliary cancers.
    Saoudi González N; Castet F; Élez E; Macarulla T; Tabernero J
    Front Oncol; 2022; 12():1021772. PubMed ID: 36300092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer.
    Xu D; Luo Y; Wang P; Li J; Ma L; Huang J; Zhang H; Yang X; Li L; Zheng Y; Fang G; Yan P
    Front Oncol; 2023; 13():1148131. PubMed ID: 37384288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data.
    Hansen TF; Qvortrup C; Pfeiffer P
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33804554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer.
    Dazio G; Epistolio S; Frattini M; Saletti P
    J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. What is the Current Role of Immunotherapy for Colon Cancer?
    Galanternik F; Recondo G; Valsecchi ME; Greco M; Recondo G; de la Vega M; E Diaz Cantón
    Rev Recent Clin Trials; 2016; 11(2):93-8. PubMed ID: 27028968
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of endoglin and VEGF family expression in colorectal cancer prognosis and anti-angiogenic therapies.
    Martins SF; Reis RM; Rodrigues AM; Baltazar F; Filho AL
    World J Clin Oncol; 2011 Jun; 2(6):272-80. PubMed ID: 21773077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(25):1-49. PubMed ID: 23074403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance Mechanisms to Anti-angiogenic Therapies in Cancer.
    Haibe Y; Kreidieh M; El Hajj H; Khalifeh I; Mukherji D; Temraz S; Shamseddine A
    Front Oncol; 2020; 10():221. PubMed ID: 32175278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vessel co-option and resistance to anti-angiogenic therapy.
    Kuczynski EA; Reynolds AR
    Angiogenesis; 2020 Feb; 23(1):55-74. PubMed ID: 31865479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Developing Story of Predictive Biomarkers in Colorectal Cancer.
    Boussios S; Ozturk MA; Moschetta M; Karathanasi A; Zakynthinakis-Kyriakou N; Katsanos KH; Christodoulou DK; Pavlidis N
    J Pers Med; 2019 Feb; 9(1):. PubMed ID: 30736475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging.
    Corrias G; Lai E; Ziranu P; Mariani S; Donisi C; Liscia N; Saba G; Pretta A; Persano M; Fanni D; Spanu D; Balconi F; Loi F; Deidda S; Restivo A; Pusceddu V; Puzzoni M; Solinas C; Massa E; Madeddu C; Gerosa C; Zorcolo L; Faa G; Saba L; Scartozzi M
    Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38611042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hallmarks in colorectal cancer: angiogenesis and cancer stem-like cells.
    Mathonnet M; Perraud A; Christou N; Akil H; Melin C; Battu S; Jauberteau MO; Denizot Y
    World J Gastroenterol; 2014 Apr; 20(15):4189-96. PubMed ID: 24764657
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.